Objective-CD36 is expressed on multiple cell types and has numerous functions, a subset of which can impact on atherogenesis.
C ellular cholesterol homeostasis is tightly regulated such that cells have an adequate supply under varying dietary conditions. 1 For most cell types, excessive accumulation of cholesterol does not occur and would have toxic implications. 2 Macrophages, by virtue of their scavenger function, internalize cholesterol-laden modified lipoproteins. Uncontrolled cholesterol accumulation in macrophages may result as an adaptive mechanism in response to excessive lipid load and lead to foam cell formation. These appear grossly as the initial lesion in atherosclerosis, the fatty streak. 3 Oxidative modification of low-density lipoprotein (LDL) has been hypothesized to be a key event in the conversion of LDL to a pro-atherogenic form recognized by macrophage scavenger receptors. 4, 5 Thus, internalization of oxidized LDL (OxLDL) by macrophages is an early and potentially pivotal event which, if inhibited through intervention at the level of the scavenger receptor, may delay the atherosclerotic process.
Previous in vitro work has supported a significant role for the class B scavenger receptor, CD36, in atherogenesis. 6, 7 We and others demonstrated that CD36 bound OxLDL in a saturable manner; binding, internalization, and degradation of OxLDL were increased substantially in CD36 transfected cells. 6 -8 Regulation of CD36 expression was also highly suggestive of an important role in atherosclerosis. 9 -15 Unlike the LDL receptor, which is downregulated by cellular cholesterol/cholesterol ester, expression of CD36 was enhanced by cellular cholesterol/cholesterol ester content and downregulated by its depletion. 10 We also showed that IL-4 and macrophage-colony stimulating factor cytokines present in atherosclerotic lesions, induced human monocyte expression of CD36 mRNA and protein, and that greater than half of the binding of OxLDL by human monocyte-derived macrophages was inhibited by specific anti-CD36 antibodies. 7, 11, 12 Other studies have demonstrated that lipid-laden macrophages in human atherosclerotic lesions exhibited strong immunoreactivity to CD36, whereas in these same lesions there were low or moderate levels of immunoreactivity to the class A scavenger receptors. 16 Genetic polymorphisms have been identified in Asian and African populations, which can lead to deficient or absent expression of CD36. 17, 18 Monocyte-derived macrophages isolated from homozygous mutant patients bound 40% less OxLDL and accumulated 40% less cholesterol ester than cells derived from normal controls. 19 More recently, using macrophages derived from mice lacking both CD36 and the class A scavenger receptors, we demonstrated that the predominant receptor involved in recognition of pro-atherogenic LDL (either mildly oxidized by copper sulfate or oxidized by the myeloperoxide/hydrogen peroxide/nitrite system) was CD36; the combined effect of absence of both scavenger receptors was not significantly greater than absence of CD36 alone. 5 CD36 is expressed on multiple cell types in addition to monocytes/macrophages: adipocytes, skeletal muscle, platelets, megakaryocytes, microvascular endothelium, retinal pigment epithelium, and microglia. 20 -22 CD36 recognizes a broad array of ligands including OxLDL, anionic phospholipids, apoptotic cells, thrombospondin, collagen, effete photoreceptors, fatty acids, fibril ␤-amyloid deposits, and Plasmodium falciparum-infected erythrocytes. 20 -22 Unlike the class A receptors, which recognize the oxidized apoprotein portion of the lipoprotein particle, CD36 binds to the lipid moiety of OxLDL, and is competed by anionic phospholipids. 7, 23 Recently, the specific ligands for CD36 on OxLDL have been defined as a family of structurally related oxidized choline glycerophospholipids. 24, 25 It is important to note that scavenger receptors are expressed on tissues other than macrophages that may effect disease outcome. This is especially true of CD36: fat and muscle are considered to be key tissues affecting insulin resistance, and both express CD36. CD36 is involved in fatty acid transport, and this has implications for fatty acid, glucose, and lipoprotein metabolism, which in turn has the potential to impact on atherosclerosis. CD36 is also expressed on microvascular endothelium, where it mediates a pro-apoptotic, anti-angiogenic response to thrombospondin-1, and this may also impact lesion development. 26 In a previous study, we observed that CD36-null mice crossed to the apo E-null (Apo E 0 ) strain had a dramatic decrease in aortic lesion area. 27 Interestingly, these results were confirmed indirectly by a study of the mechanism by which drugs used to treat HIV accelerated atherosclerosis. 28 One such drug, ritonavir, upregulates CD36 and promotes lesion progression in the Apo E 0 mouse. This effect was abrogated in Apo E 0 /CD36 0 mice, and the authors noted a 75% to 80% difference in lesion size in the 2 strains when treated with ritonavir. Their results indicate that upregulation of CD36 by a drug mimics upregulation of CD36 in the subendothelial space by pro-inflammatory factors, which also convert LDL into a ligand for CD36 and initiate a feedforward loop in macrophages. 14, 15 The degree of protection afforded by absence of CD36 was nearly identical to our results. 27 The current study was designed to differentiate the role of CD36 as a macrophage scavenger receptor from other functions it has in endothelium, muscle, adipocytes, and in regulating fatty acid transport and angiogenesis. Using stem cell transfer, the genotype of hematopoietic cells, including monocytes/macrophages, was exchanged in the background of presence or absence of CD36 in the Apo E 0 model. Our results suggest rather conclusively that in the Apo E 0 model, absence of macrophage CD36 is overwhelmingly protective, regardless of CD36 expression elsewhere, and indicates that specifically targeting macrophage CD36 can have important therapeutic implications. 
Methods

Animals
Stem Cell Transfer
One week before transplantation until 2 weeks after transplantation, recipient mice received 100 mg/L neomycin and 10 mg/L polymyxin B sulfate in acidified water. At 6 weeks of age, Apo E 0 and CD36 0 /Apo E 0 mice were lethally irradiated (9 gray from a cesium gamma source; Gamma Cell 40). Four hours later, 1ϫ10
7 bone marrow cells (from background-and gender-matched mice 6 to 12 weeks of age) were injected into the tail vein. Recipient mice received normal chow for 4 weeks. For the next 12 weeks, mice were fed a high-fat diet: 21% (wt/wt) adjusted calories from fat and 1.5% (wt/wt) cholesterol (no cholate; Harlan Teklad, TD 88137).
Assessment of Chimerism
Resident macrophages were collected by phosphate-buffered saline lavage. DNA was purified after proteinase K lysing by phenolchloroform extraction/ethanol precipitation. For polymerase chain reaction of CD36, primers for the wild-type allele were: 5Ј CD36: CAGCTCATACATTGCTGTTTATGCATG; 3Ј CD36: GGTA-CAATCACAGTGTTTTCTACGTGG (expected product Ϸ600 bp). For the null allele, the same 5Ј primer was used and the 3Ј primer was CCGCTTCCTCGTGCTTTACGGTATC (expected product Ϸ800 bp). With all 3 primers present, polymerase chain reaction conditions were: 94°C, 1 minute; 65°C, 1 minute; and 70°C, 2 minutes, for 30 cycles.
Polymerase chain reaction at 12 weeks after irradiation showed varying degrees of chimerism, as has been reported by others ( Figure  I , available online at http://atvb.ahajournals.org). The majority of the animals screened had predominantly donor-derived marrow.
Assessment of Engraftment
Male mice receiving heterogeneic marrow were assessed 14 weeks after irradiation (nϭ6/group) by flow cytometry to determine total white blood cell count. Equal volumes of blood were collected from the tail vein into heparinized tubes. After red cells were lysed, 10 000 Flow-Check Fluorospheres (Beckman Coulter) were added for volume quantification. Gates were set to include all white cells.
Morphometry
Hearts were perfused with phosphate-buffered saline and buffered formalin. The entire aorta from the heart, extending 5 to 10 mm after bifurcation of the iliacs and including the subclavian, right, and left carotid arteries, was dissected free of fat and opened longitudinally. After staining with oil red O, aortae were scanned and percent lesion area determined using Adobe Photoshop. Lesion area is expressed as percentϮSE.
Assessment of Lesion Morphology
Hearts from male mice representing each group were infiltrated with 30% sucrose after fixation and embedded in OCT. Ten-micron sections were cut at the level of the aortic sinus. Slides were either stained with oil red O or processed for immunohistochemistry with a macrophage-specific antibody (F4/80; Abcam), and counterstained with aqueous hematoxylin. Digital images of lesions at 200ϫ magnification (Magnafire software) were assessed using Adobe Photoshop for percent oil red O or F4/80 positivity.
Glucose Tolerance Testing
Mice fasted overnight received an intraperitoneal injection of 1.5 mg glucose per gram of body weight. Tail vein blood was collected at intervals up to 120 minutes and glucose measured using a One Touch Basic glucometer (Johnson & Johnson). Area under the curve was calculated using Graph Pad Prism 4 software, with individual baseline values set to control for the fasting hypoglycemia of mice lacking CD36.
Plasma Analyses
One week before euthanization, mice were fasted and blood collected for analysis. Total, LDL, and high-density lipoprotein (HDL) cholesterol and triacylglycerol were determined using kits from Sigma Diagnostics. (Note: the EZ-HDL cholesterol kit does not involve precipitation of HDL, which proved unreliable for determination of HDL levels in Apo E 0 mice.) Nonesterified fatty acid concentration was determined using a kit from Wako.
Macrophage Recruitment Assay
Sterile thioglycollate broth (4%; Sigma) was injected into the peritoneal cavity of male mice (2 mL, nϭ4) receiving heterogeneic marrow 4 days before euthanization, 16 weeks after irradiation. Total elicited macrophages were collected by phosphate-buffered saline lavage and counted using a hemocytometer.
Statistical Analyses
Significance was determined by Student unpaired t test before irradiation and ANOVA, followed by Bonferroni multiple comparison test after irradiation. PϽ0.05 was considered significant. Figure 1D and 1E.
Results
Apo
Extensive analyses were performed to rule out an effect of irradiation and reconstitution with bone marrow-derived stem cells on parameters such as weight gain, plasma glucose, and lipid metabolism. Before irradiation, baseline values of weight, cholesterol, triacylglycerol, glucose, and nonesterified fatty acids were determined (Table I , available online at http://atvb.ahajournals.org). CD36 0 /Apo E 0 male mice were significantly heavier and had significantly higher triacylglycerol and nonesterified fatty acid levels compared with Apo E 0 male mice. Both male and female CD36 0 /Apo E 0 mice had significantly higher total cholesterol levels and fasting hypoglycemia as compared with Apo E 0 mice. The increased weight in the CD36 0 /Apo E 0 males may reflect many parameters, including litter size, which was not controlled for in this study. The increased cholesterol, triacylglycerol and fatty acids, and hypoglycemia may be attributed to the phenotype of absence of CD36 in its capacity as a fatty acid transporter, and were noted previously in the CD36-null. As demonstrated by fast protein liquid chromatography analysis in a previously published study, excess triacylglycerol in CD36 0 /Apo E 0 mice was contained within the very-low-density lipoprotein fraction, whereas excess cholesterol was contained within the very-low-density lipoprotein and LDL fractions. These studies indicated that CD36 0 /Apo E 0 mice had fatty acid and lipoprotein profiles that may be considered more proatherogenic as compared with Apo E 0 mice. Before irradiation, both male and female Apo E 0 and CD36 0 /Apo E 0 mice cleared a bolus of glucose with similar kinetics ( Figure IIA and IIB, available online at http:// atvb.ahajournals.org), and there were no significant differences in area under the curve. After irradiation and 8 weeks after the start of the high-fat diet, glucose tolerance testing was repeated in the different groups of mice, and there still were no significant differences in area under the curve ( Figure IIC and IID) .
At euthanization, there were no significant differences in weight, total cholesterol, HDL cholesterol, LDL cholesterol, and nonesterified fatty acids among the groups (Table II , available online at http://atvb.ahajournals.org). There were significant differences in triacylglycerol in female mice. There were significantly higher levels of triacylglycerol in Apo E 0 females receiving Apo E 0 marrow when compared with Apo E 0 females receiving CD36 0 /Apo E 0 marrow or CD36 0 /Apo E 0 females receiving CD36 0 /Apo E 0 marrow. CD36 0 /Apo E 0 mice of both sexes retained their fasting hypoglycemia after irradiation, regardless of genotype of bone marrow received.
To rule out possible differences in stem cell engraftment, we compared total white blood counts in mice (nϭ6/group) 14 weeks after irradiation. Apo E 0 mice receiving CD36 0 /Apo E 0 bone marrow had 5981Ϯ689 white blood cells per microliter of blood compared with 6170Ϯ578 white blood cells per microliter in CD36 0 /Apo E 0 mice receiving Apo E 0 marrow. These values do not differ statistically and rule out this as a possible explanation for the decrease in lesions.
We also ruled out differences in macrophage recruitment as a potential explanation of our results in 2 ways. First, we used thioglycollate elicitation of peritoneal macrophages 16 weeks after irradiation as an assay of macrophage recruitment to a pro-inflammatory stimulus (nϭ4). In Apo E 0 mice receiving CD36 0 /Apo E 0 bone marrow, we collected a total of 3.05Ϯ0.21ϫ10 7 macrophages. This was not different statistically from the 3.19Ϯ0.15ϫ10 7 macrophages collected from CD36 0 /Apo E 0 mice receiving Apo E 0 marrow. To rule out the possibility that after irradiation there were differences in the ability of macrophages to migrate into lesions, hearts from a random sample of male mice from each group were sectioned at the level of the aortic sinus, stained with oil red O or immunohistochemically with a macrophagespecific antibody, and assessed microscopically. There were no obvious differences in lesion morphology among the groups; in all cases, a substantial proportion (mean percent area: 47 to 60) of the lesion consisted of oil red O-positive lipid. Apo E 0 mice receiving Apo E 0 marrow had the greatest percent oil red O lesion area, and this was statistically significant when compared with Apo E 0 mice receiving CD36 0 /Apo E 0 marrow and CD36 0 /Apo E 0 receiving CD36 0 / Apo E 0 marrow (Figure 2A ). CD36 0 /Apo E 0 receiving Apo E 0 also had significantly greater oil red O-positive lesion area when compared with these 2 groups. However, there were no significant differences in F4/80 positivity among the groups (mean percent area: 15.31 to 17.13) ( Figure 2B ). Thus, our data strongly suggest that differences in lesion development were not related to a defect in macrophage stem cell engraftment after irradiation in any of the groups, and instead appear to reflect differences in lipid accumulation within individual macrophages.
Discussion
In previous work, we demonstrated that absence of CD36 had a profound effect on atherosclerotic lesion formation in the Apo E 0 model. 27 Because CD36 expression is broad and has functions other than that of a scavenger receptor, there was the potential that these other roles were involved in the observed protective effect. In the present study, we controlled for the other functions of CD36 by transplanting hematopoi-etic stem cells, allowing us to isolate the scavenger receptor function of macrophage CD36 from most other functions. Our data provide strong support for the hypothesis that inhibition of CD36 function in macrophages alone will have large therapeutic impact.
This contention is supported in 2 ways. Absence of CD36 in macrophages transplanted into mice that expressed CD36 in all other nonhematopoietic tissues resulted in an 88.1% decrease in aortic lesions. Alternatively, presence of CD36 only in macrophages resulted in a 52.7% increase in lesion area. The lesion area in this group was nearly indistinguishable from atherosclerosis in Apo E 0 mice transplanted with syngeneic marrow. These results provide strong rationale for therapeutic blockade of macrophage CD36 to slow atherogenesis.
There is a nonstatistically significant trend in the data that suggests that absence of CD36 in macrophages is more protective than whole-body absence of CD36. This intriguing result points to the multifaceted nature of this protein. It is possible that CD36 expression and function as a fatty acid transporter in adipocytes and muscle may provide a level of protection against atherosclerosis. For example, perhaps use of lipoproteins by these tissues decreases potential for oxidation.
It is theoretically possible that the effect we observed is a result of endothelial cell CD36 rather than macrophage CD36. We rule this out for several reasons. First, CD36 is expressed on microvascular endothelium and, thus, the vessels examined are not likely to express endothelial CD36. Second, Ϸ0.1% of in vivo endothelium turns over each day.
Even if we were to assume that all new endothelium was stem cell-derived (which is probably not the case), 4 months after irradiation Ͻ15% of the endothelium in irradiated mice would be donor-derived. The dramatic nature of our results, we believe, is more consistent with an effect on macrophages, although an additional effect from CD36 absence on endothelial cells is also possible.
It is also possible that our results reflect differences in stem cell engraftment (and thus macrophage number) or macrophage recruitment because of a mismatch of the genotype of donor and recipient. We compared total white cell number between Apo E 0 mice receiving CD36 0 /Apo E 0 marrow with that of CD36 0 /Apo E 0 receiving Apo E 0 marrow and observed no statistical difference. We also found no difference in macrophage numbers in the peritoneal cavity after thioglycollate elicitation in these chimeras, indicating that there is no defect in macrophage ability to detect, react, and traffic to the site of an inflammatory stimulus caused by genotype mismatch. Finally, quantitative assessment of oil red O-positive lipid in lesion and area positive for a macrophage-specific antigen suggest similarity in overall lesion morphology but a difference in lipid accumulation.
In the studies contained in this report, we saw very few differences between the groups of mice after irradiation, with the exception of fasting hypoglycemia in CD36 0 hosts. Nonesterified fatty acids and total, HDL, and LDL cholesterol showed no statistically significant differences. Apo E 0 female mice receiving Apo E 0 bone marrow had significantly higher triacylglycerol levels when compared with CD36 0 /Apo E 0 females receiving Apo E 0 or CD36 0 /Apo E 0 marrow. However, Apo E 0 females receiving CD36 0 /Apo E 0 marrow had similar triacylglycerol levels to CD36 0 /Apo E 0 females receiving Apo E 0 marrow, yet the lesion data were strictly dependent on the genotype of the engrafted cells. This strongly argues against alterations in plasma triacylglycerol levels playing a significant role. After irradiation and on the Western diet, all groups of mice showed some degree of insulin resistance. However, the absence of significant differences between the groups again strongly argues against an effect on pathogenesis in any one group.
The mechanism of protection afforded by absence of CD36 may be more than simple lack of macrophage uptake of OxLDL. OxLDL promotes a pro-inflammatory phenotype in macrophages and endothelial cells. Absence of CD36 may indirectly delay lesion progression by interfering with the expression of pro-inflammatory products, thereby delaying or inhibiting recruitment of other cells and secretion of cytokines and pro-oxidative factors involved in atherogenesis. We and others have shown that OxLDL and 2 oxidized linoleic acid metabolites, 9-HODE and 13-HODE, can stimulate CD36 gene expression via a mechanism involving activation of peroxisome proliferator-activated receptor (PPAR)-␥, a member of the nuclear hormone superfamily, which acts as a transcriptional regulator of genes encoding proteins involved in lipid and fatty acid metabolism/regulation, as well as inflammation. 13-15,29 -32 Absence of CD36 negates this feedforward loop and may not only alter the lipid metabolism state of the macrophage but also alter the inflammatory state of these cells, and this may account for the profound decrease in lesion formation observed.
